fda glp-1 Pharmacovigilance Assessment of Compounded Receptor Agonists: Insights From the Adverse Event Reporting System GLP-1 Injections for Medical Weight
Description
Consequently, on top of the beneficial effect of weight loss caused by GLP-1 analogues these drugs also cause a substantial reduction of the glycemic load (GL = carbohydrate intake X Glycemic index), which per se reduces hyperinsulinemia and causes weight loss [22], reduce diabetes risk [23], inflammation [24], and cardiovascular risk [25]
Funding Nil
Precision-based assessment before and during treatment may identify responders and non-responders earlier
The 2.5mg starting dose is subtherapeutic for weight loss
